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Activation of the cystic ﬁbrosis transmembrane conductance
regulator chloride channel drives ﬂuid secretion in the
intestine. High-throughput screening identiﬁed a small-
molecule cystic ﬁbrosis transmembrane conductance regu-
lator activator that increases intestinal ﬂuid secretion. Oral
administration of the activator corrected constipation in a
mouse model.
BACKGROUND & AIMS: Constipation is a common clinical
problem that negatively impacts quality of life and is associated
with signiﬁcant health care costs. Activation of the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) chloride
channel is the primary pathway that drives ﬂuid secretion in
the intestine, which maintains lubrication of luminal contents.
We hypothesized that direct activation of CFTR would cause
ﬂuid secretion and reverse the excessive dehydration of stool
found in constipation.
METHODS: A cell-based, high-throughput screen was per-
formed for 120,000 drug-like, synthetic small molecules. Active
compounds were characterized for mechanism of action and
one lead compound was tested in a loperamide-induced con-
stipation model in mice.
RESULTS: Several classes of novel CFTR activators
were identiﬁed, one of which, the phenylquinoxalinone
CFTRact-J027, fully activated CFTR chloride conductance with
an half-maximal effective concentration (EC50) of approxi-
mately 200 nmol/L, without causing an increase of cyto-
plasmic cyclic adenosine monophosphate. Orally
administered CFTRact-J027 normalized stool output and wa-
ter content in a loperamide-induced mouse model of con-
stipation with a 50% effective dose of approximately 0.5 mg/
kg; CFTRact-J027 was without effect in cystic ﬁbrosis mice
lacking functional CFTR. Short-circuit current, ﬂuid secretion,
and motility measurements in mouse intestine indicated a
prosecretory action of CFTRact-J027 without direct stimula-
tion of intestinal motility. Oral administration of 10 mg/kg
CFTRact-J027 showed minimal bioavailability, rapid hepatic
metabolism, and blood levels less than 200 nmol/L, and
without apparent toxicity after chronic administration.
CONCLUSIONS: CFTRact-J027 or alternative small-molecule
CFTR-targeted activators may be efﬁcacious for the treatmentof constipation. (Cell Mol Gastroenterol Hepatol 2016;2:317–327;
http://dx.doi.org/10.1016/j.jcmgh.2015.12.010)
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onstipation is a common clinical complaint in adultsCand children that negatively impacts quality of life.
The prevalence of chronic constipation has been estimated
to be 15% in the US population, with annual health care
costs estimated at approximately 7 billion dollars, with
more than 800 million dollars spent on laxatives.1,2 The
mainstay of constipation therapy includes laxatives that
increase stool bulk, such as soluble ﬁber; creation of an
osmotic load, such as polyethylene glycol; or stimulation of
intestinal contraction, such as the diphenylmethanes. There
also are surface laxatives that soften stool such as docusate
sodium and probiotics such as Lactobacillus paracasei.3 The
Food and Drug Administration–approved drug linaclotide, a
peptide agonist of the guanylate cyclase C receptor, acts by
inhibiting visceral pain, stimulating intestinal motility, and
increasing intestinal secretion.4,5 A second approved drug,
lubiprostone, a prostaglandin E analog, is thought to activate
a putative enterocyte ClC-2 channel,6 although the mecha-
nistic data are less clear. Despite the wide range of thera-
peutic options, there is a continued need for safe and
effective drugs to treat constipation.
Intestinal ﬂuid secretion involves active Cl- secretion
across the enterocyte epithelium through the basolateral
membrane Naþ/ Kþ/ 2Cl- cotransporter, the luminal mem-
brane cystic ﬁbrosis transmembrane conductance regulator
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electrochemical and osmotic forces created by Cl- secretion
drive Naþ and water secretion.7 In cholera and traveler’s
diarrhea, CFTR is activated strongly by bacterial entero-
toxins through increase of intracellular cyclic nucleotides.8,9
CFTR is an attractive target to increase intestinal ﬂuid
secretion in constipation because it is expressed robustly
throughout the intestine and its activation can strongly in-
crease intestinal ﬂuid secretion. An activator targeting CFTR
directly is unlikely to produce the massive, uncontrolled
intestinal ﬂuid secretion seen in cholera because the en-
terotoxins in cholera act irreversibly to produce a sustained
increase of cytoplasmic cyclic adenosine monophosphate
(cAMP), which not only activates CFTR but also basolateral
Kþ channels, which increase the electrochemical driving
force for Cl- secretion; cholera enterotoxins also inhibit the
luminal NHE3 Naþ/Hþ exchanger involved in intestinal ﬂuid
absorption.10,11
Motivated by these considerations and the continuing
need for safe and effective drug therapy of constipation, we
report the identiﬁcation and characterization of a nano-
molar potency, CFTR-targeted, small-molecule activator, and
provide proof of concept for its prosecretory action in the
intestine and efﬁcacy in constipation.
Materials and Methods
Materials
High-throughput screening was performed using a
diverse collection of 120,000 drug-like synthetic com-
pounds obtained from ChemDiv, Inc (San Diego, CA) and
Asinex (Winston-Salem, NC). For structure-activity analysis,
600 commercially available analogs (ChemDiv, Inc) of active
compounds identiﬁed in the primary screen were tested.
Other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO) unless indicated otherwise.
CFTRact-J027 Synthesis
Potassium carbonate (2.5 g, 18.4 mmol) and benzyl
bromide (0.73 mL, 6.2 mmol) were added to a solution of
o-phenylenediamine (1 g, 9.24 mmol) in dimethylformamide
(DMF) (30 mL), and then stirred overnight at ambient
temperature. The reaction mixture was diluted with CH2Cl2,
washed with water, dried over MgSO4, and concentrated
under reduced pressure. The residue was puriﬁed by ﬂash
chromatography to yield the intermediate N1-benzylben-
zene-1,2-diamine as a brown liquid. 1H NMR (300 MHz,
CDCl3): d 7.45–7.31 (m, 5H), 6.86–6.69 (m, 4H), 4.35 (s, 2H),
3.50 (br, 3H); MS: m/z 199 (MþH)þ. Then, a solution of the
intermediate (400 mg, 2 mmol) and 5-nitroisatin (380 mg, 2
mmol) in acetic acid (5 mL) was reﬂuxed for 2 hours. The
reaction mixture was cooled to room temperature and sol-
vent was removed under reduced pressure. The residue was
dissolved with methanol to crystallize 3-(2-amino-5-
nitrophenyl)-1-benzylquinoxalin-2(1H)-one (CFTRact-
J027) as a yellow solid with more than 99% purity. 1H NMR
(300 MHz, [DMSO] d6): d 9.15 (d, 1H, J ¼ 2.8 Hz), 8.07 (dd,
1H, J ¼ 2.7, 9.2 Hz), 7.97 (dd, 1H, J ¼ 1.2, 7.9 Hz), 7.82 (br,
2H), 7.60-7.27 (m, 7H), 6.92 (d, 1H, J ¼ 9.2 Hz), 5.59 (br,2H); 13C NMR (75 MHz, DMSO-d6): d 155.0, 154.6, 153.3,
136.3, 135.3, 132.8, 132.2, 131.0, 130.0, 129.5, 129.1, 127.7,
127.3, 126.8, 124.1, 116.1, 115.9, 115.4, 45.9; MS: m/z 373
(MþH)þ.
Cell Culture
Fischer rat thyroid (FRT) cells stably co-expressing
human wild-type CFTR and the halide-sensitive yellow ﬂuo-
rescent protein (YFP)-H148Q were generated as previously
described.12 Cells were cultured on plastic in Coon’s-modi-
ﬁed Ham’s F12 medium supplemented with 10% fetal bovine
serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100
mg/mL streptomycin. For high-throughput screening, cells
were plated in black 96-well microplates (Corning-Costar
Corp, Corning, NY) at a density of 20,000 cells per well.
Screening was performed 24–48 hours after plating.
High-Throughput Screening
Screening was performed using a Beckman Coulter
(Brea, CA) integrated system equipped with a liquid
handling system and 2 FLUOstar ﬂuorescence plate readers
(BMG Labtechnologies, Durham, NC), each equipped with
dual syringe pumps and 500 ± 10 nm excitation and 535 ±
15 nm emission ﬁlters (see Galietta et al12 for more detail).
CFTR- and YFP-expressing FRT cells were grown at 37C/
5% CO2 for 24–48 hours after plating. At the time of assay,
cells were washed 3 times with phosphate-buffered saline
(PBS) and then incubated for 10 minutes with 60 mL of PBS
containing test compounds (at 10 mmol/L) and a low con-
centration of forskolin (125 nmol/L). Each well was assayed
individually for I- inﬂux in a plate reader by recording
ﬂuorescence continuously (200 ms/point) for 2 seconds
(baseline) and then for 12 seconds after rapid (<1 s)
addition of 165 mL of PBS in which 137 mmol/L Cl- was
replaced by I-. The initial rate of I- inﬂux was computed by
determining exponential regression. All compound plates
contained negative controls (DMSO vehicle) and positive
controls (20 mmol/L forskolin).
Short-Circuit Current Measurement
Short-circuit current was measured in FRT cells stably
expressing wild-type human CFTR cultured on porous ﬁlters
as described.12 The basolateral solution contained (in
mmol/L): 130 NaCl, 2.7 KCl, 1.5 KH2PO4, 1 CaCl2, 0.5 MgCl2,
10 glucose, and 5 Na-HEPES (pH 7.3, 37C). In the apical
solution, 65 mmol/L NaCl was replaced by Na gluconate, and
CaCl2 was increased to 2 mmol/L, and the basolateral mem-
brane was permeabilized with 250 mg/mL amphotericin B.
Short-circuit current was measured in freshly harvested adult
mouse colon at 37C using symmetric Krebs-bicarbonate
buffer (pH 7.4, in mmol/L: 117 NaCl, 4.7 KCl, 1.2 MgCl2, 2.5
CaCl2, 11.1 D-glucose, 1.2 KH2PO4, and 24.8 NaHCO3).
cAMP Assay
Intracellular cAMP activity was measured using a Glo-
Sensor luminescence assay (Promega Corp, Madison, WI).
FRT null cells were stably transfected with the pGloSensor
Figure 1. Identiﬁcation of small-molecule CFTR activators. (A) Project overview. (B) CFTR activator screen using FRT cells
co-expressing human wild-type CFTR and YFP iodide–sensing protein. Test compounds at 10 mmol/L were added for 10
minutes at room temperature in the presence of forskolin (125 nmol/L) before iodide addition. Examples of data from single
wells of a 96-well plate showing CFTR activation by CFTRact-J027 are shown. (C) Structures of CFTR activators emerging from
the screen. (D) Synthesis of CFTRact-J027. DMF, dimethylformamide.
May 2016 CFTR Activator for Constipation 319cAMP plasmid and plated on white 96-well microplates and
grown to conﬂuence. Cells were washed 3 times with PBS
and incubated with 5 mmol/L CFTRact-J027 for 10 minutes
in the absence and presence of 100 nmol/L forskolin. cAMP
was assayed according to the manufacturer’s instructions.
Animals
Animal experiments were approved by the University of
California San Francisco Institutional Animal Care and Use
Committee. Animals were housed in communal cages with
standard rodent chow and water available ad libitum. Wild-
type CD1 mice and CFTR DF508 homozygous mice were
bred in the University of California San Francisco Labora-
tory Animal Resource Center.
Pharmacokinetics
Female CD1 mice were treated with 10 mg/kg CFTRact-
J027 (saline containing 5% DMSO and 10% Kolliphor HS 15)
either intraperitoneally (IP) or orally. Blood was collected at
15, 30, 60, 150, 240, and 360 minutes after treatment by
orbital puncture and centrifuged at 5000 rpm for 15
minutes to separate plasma. Plasma samples (60 mL) were
mixed with 300 mL acetonitrile and centrifuged at 13,000
rpm for 20 minutes, and 90 mL of the supernatant was used
for liquid chromatography–mass spectrometry. The solvent
system consisted of a linear gradient from 5% to 95%
acetonitrile over 16 minutes (0.2 mL/min ﬂow). Mass
spectra was acquired on a mass spectrometer (Waters 2695
and Micromass ZQ, Milford, MA) using electrospray (þ)
ionization, mass ranged from 100 to 1500 daltons, conevoltage was 40 V. Calibration standards were prepared in
plasma from untreated mice, to which known amounts of
CFTRact-J027 were added.
In Vitro Metabolic Stability
CFTRact-J027 (5 mmol/L) was incubated for speciﬁed
times at 37C with mouse liver microsomes (1 mg protein/
mL; Sigma-Aldrich) in potassium phosphate buffer
(100 mmol/L) containing 1 mmol/L reduced nicotinamide
adenine dinucleotide phosphate, as described.13 The mix-
ture then was chilled on ice, and 0.5 mL of ice-cold ethyl
acetate was added. Samples were centrifuged for 15
minutes at 3000 rpm, the supernatant evaporated to dry-
ness, and the residue was dissolved in 100 mL mobile phase
(acetonitrile:water, 3:1) for liquid chromatography–mass
spectrometry and assayed as described earlier.
Murine Model of Constipation
Female CD1 mice (age, 8–10 wk) were administered
loperamide (0.3 mg/kg, IP; Sigma-Aldrich) to produce con-
stipation. Various amounts of CFTRact-J027 (0.1, 0.3, 1, 3,
and 10 mg/kg) were given at the same time (for IP
administration) or 1 hour before (for oral administration)
loperamide. Control mice were treated with vehicle
only. Some mice were treated orally with lubiprostone
(0.5 mg/kg; Sigma-Aldrich) or linaclotide (0.5 mg/kg; Tor-
onto Research Chemicals, Inc, Toronto, Ontario, Canada).
After loperamide injection, mice were placed individually in
metabolic cages with food and water provided ad libitum.
Stool samples were collected for 3 hours, and total stool
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measure stool water content the stool samples were dried at
80C for 24 hours and water content was calculated as
follows: (wet weight - dry weight)/wet weight. Similar
studies were performed in cystic ﬁbrosis mice (DF508 ho-
mozygous) lacking functional CFTR. Some studies were
performed using the chemically similar but inactive analog
of CFTRact-J027: 3-(2-amino-5-nitrophenyl)-1-(methyl)-
2(1H)-quinoxalinone.
In Vivo Intestinal Transit and Ex Vivo
Intestinal Contractility
Whole-gut transit time was determined using an orally
administered marker (200 mL, 5% Evans Blue, 5% gum
Arabic) and measuring the time of its appearance in stool.
Mice were administered loperamide and CFTRact-J027
(10 mg/kg) or vehicle intraperitoneally at zero time. For
ex vivo contractility measurements, mice were euthanized
by avertin overdose (200 mg/kg, 2,2,2-tribromethanol;
Sigma-Aldrich) and ileum and colon segments of approxi-
mately 2-cm length were isolated and washed with
Krebs–Henseleit buffer (pH 7.4, in mmol/L: 118 NaCl, 4.7
KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 2.5 CaCl2, and 11
D-glucose). The ends of the intestinal segments were tied,
connected to a force transducer (Biopac Systems, Goleta,
CA), and tissues were transferred to an organ chamber
(Biopac Systems) containing Krebs–Henseleit buffer at 37C
aerated with 95% O2, 5% CO2. Ileum and colon were sta-
bilized for 60 minutes with resting tensions of 0.5 and 0.2 g,
respectively, and solutions were changed every 15 minutes.
Effects of CFTRact-J027 on baseline and loperamide-
suppressed isometric intestinal contractions were recorded.
In Vivo Intestinal Secretion and Absorption
Mice (wild-type or CF) were given access to 5% dextrose
water but not solid food for 24 hours before experiments.
Mice were anesthetized with isoﬂurane, and body temper-
ature was maintained during surgery at 36C –38C using a
heating pad. A small abdominal incision was made to
expose the small intestine, and closed midjejunal loops
(length 2–3 cm) were isolated by sutures. Loops were
injected with 100 mL vehicle alone or 100 mg CFTRact-J027
in vehicle. The abdominal incision was closed with sutures,
and mice were allowed to recover from anesthesia. Intesti-
nal loops were removed at 90 minutes and loop length and
weight were measured to quantify ﬂuid secretion. Intestinal
absorption was measured in CF mice (to prevent secretion)
as described earlier, except that the loops were removed
at 0 or 30 minutes. Absorption was calculated as follows:
1 - loop weight at 30 minutes)/loop weight at 0 minutes.
Chronic Administration and Toxicity Studies
Mice were administered 10 mg/kg CFTRact-J027 or
vehicle orally once a day for 7 days. One hour after the ﬁnal
dose mice were treated with loperamide (0.3 mg/kg, IP) and
stool was collected for 3 hours. In vivo toxicity was assessed
in these mice by measuring the lung wet/dry weight ratio,
complete blood count (Hemavet 950FS; Drew Scientiﬁc, Inc,Miami Lakes, FL) and serum chemistry (Idexx Laboratories,
Inc, Sacramento, CA) 4 hours after the last CFTRact-J027
dose. In vitro cytotoxicity was measured in FRT cells incu-
bated with 25 mmol/L CFTRact-J027 for 8 and 24 hours.
Cytotoxicity was measured by Alamar Blue assay
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA).
Statistical Analysis
Experiments with 2 groups were analyzed with the
Student’s t test, when there were 3 groups or more analysis
was performed with 1-way analysis of variance and the post
hoc Newman–Keuls multiple comparisons test. A P value
less than .05 was taken as statistically signiﬁcant.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Identiﬁcation and In Vitro Characterization of
Small-Molecule CFTR Activators
The initial goal was to identify a potent, CFTR-targeted
activator with prosecretory activity in the intestine to test
its efﬁcacy in a mouse model of constipation. Figure 1A
summarizes the project strategy. The compounds evaluated
here included small molecules identiﬁed in prior CFTR acti-
vator/potentiator screens14 and from a new screen of syn-
thetic small molecules not tested previously. The most active
compounds emerging from the screen, along with commer-
cially available chemical analogs, were prioritized based on an
initial mechanism-of-action study (assay of cAMP increase),
in vitro toxicity, prosecretory action in mouse intestine,
and efﬁcacy in a mouse model of constipation. Figure 1B
shows the cell-based plate reader screening method in
which the initial rate of iodide inﬂux was measured in FRT
cells stably expressing human wild-type CFTR and a YFP
ﬂuorescent halide sensor after extracellular addition of
iodide. CFTR activation increased the initial slope of the
ﬂuorescence quenching curve. A low concentration of for-
skolin (125 nmol/L) was included in the screen to recapitu-
late the basal level of CFTR phosphorylation in vivo because
CFTR is not phosphorylated at baseline in FRT cells.15
Figure 1C shows the chemical structures of 6 classes of
candidate CFTR activators identiﬁed from the screens.
Based on the criteria listed earlier, we focused further
studies on CFTRact-J027, a 3-phenyl-quinoxalinone with
drug-like properties. CFTRact-J027 was synthesized in pure
crystalline form in 2 steps (Figure 1D).
Short-circuit current measurements in CFTR-expressing
FRT cells showed that CFTRact-J027 fully activated CFTR
(Figure 2A) because the cAMP agonist forskolin produced a
minimal further increase in current, with an EC50 of
approximately 200 nmol/L (Figure 2B). Little CFTR activa-
tion by CFTRact-J027 was seen in the absence of forskolin
(data not shown), suggesting the need for some level of
basal phosphorylation as expected in vivo. Interestingly,
CFTRact-J027 was only a weak potentiator of DF508-CFTR,
as studied in FRT cells expressing DF508-CFTR after over-
night incubation with the corrector VX-809, which promotes
Figure 2. Characterization of CFTR activation by CFTRact-J027. Short-circuit current measured in FRT cells expressing (A)
human wild-type CFTR and (C) DF508-CFTR showing responses to indicated concentrations of forskolin (fsk), CFTRact-J027,
and VX-770. The DF508-CFTR–expressing FRT cells were corrected with 3 mmol/L VX-809 at 37C for 24 hours before
measurement. CFTRinh-172 (Inh-172, 10 mmol/L) was added where indicated (representative of 3 experiments for each). (B)
CFTRact-J027 concentration-dependent activation of wild-type CFTR Cl
- current (means ± SEM; n ¼ 3 cultures). (D) Short-
circuit current in mouse colon showing responses to indicated concentrations of forskolin (fsk), CFTRact-J027, and
CFTRinh-172 (representative of 3 experiments). (E) Assay of cAMP concentration in FRT cells measured after a 10-minute
incubation with indicated concentrations of forskolin and 5 mmol/L CFTRact-J027. Positive controls included forskolin (100
nmol/L and 20 mmol/L), and forskolin plus 3-isobutyl-1-methylxanthine (IBMX, 100 mmol/L) (means ± SEM, n ¼ 4–8).
May 2016 CFTR Activator for Constipation 321plasma membrane targeting of the mutant channel
(Figure 2C). Cl- secretion in freshly isolated mouse colon
showed a concentration-dependent increase in short-circuit
current, with an EC50 of approximately 300 nmol/L
(Figure 2D). The increase in current at high CFTRact-J027
levels was increased further by forskolin, which may be a
consequence of activation of a basolateral membrane cAMP-
sensitive Kþ channel that increases the driving force for
apical membrane Cl- secretion. The increase in current was
fully reversed by a CFTR-selective inhibitor. The reduced
effect of CFTRact-J027 on intact intestine could also result
from limited drug access to the crypts or intestinal tissue
metabolism of the drug. Figure 2E shows that CFTRact-J027
does not increase cellular cAMP when added alone, and
does not increase cAMP further when added together with
forskolin, suggesting that CFTR activation by CFTRact-J027
involves a direct interaction mechanism rather than indirect
action through cAMP increase. Direct activation of protein
kinase A by CFTRact-J027 is unlikely to occur because littleor no activation of CFTR by CFTRact-J027 is seen in the
absence of a cAMP agonist.CFTRact-J027 Normalizes Stool Output in a
Mouse Model of Constipation
CFTRact-J027 was studied in a loperamide-induced
model of constipation in mice in which stool weight, pellet
number, and water content were measured for 3 hours after
intraperitoneal loperamide administration (Figure 3A).
Intraperitoneal administration of CFTRact-J027 at 10 mg/kg
normalized each of the stool parameters. CFTRact-J027 did
not affect stool output or water content in control (non-
–loperamide-treated) mice. Importantly, CFTRact-J027 was
without effect in cystic ﬁbrosis mice lacking functional CFTR
(Figure 3B). Also an inactive chemical analog of CFTRact-J027
was not effective in wild-type mice (Figure 3C). These re-
sults support a CFTR-selective action of CFTRact-J027. Also,
the lack of efﬁcacy of CFTRact-J027 in cystic ﬁbrosis mice
Figure 3. CFTRact-J027 normalizes stool output and water content in loperamide-treated mice. (A) Mouse model of
constipation with loperamide (left). Three-hour stool weight, number of pellets, and stool water content in mice (means ± SEM, 6
mice per group). (B) Same study as shown in panel A, but with cystic ﬁbrosis mice lacking functional CFTR (3–6 mice per group).
(C) Same study as shown in panel A, but with an inactive chemical analog of CFTRact-J027 (structure shown, 3 mice per group).
(D) Dose-response for intraperitoneal administration of CFTRact-J027 in loperamide-treated mice (4–6 mice per group). One-way
analysis of variance was used for panels A and B, the Student’s t test was used for panel C. *P < .05, ***P < .001.
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by opioid-receptor antagonism. Dose-response studies in
mice showed a 50% effective dose of 2 mg/kg in the
loperamide model by IP administration of CFTRact-J027
(Figure 3D).
Oral administration of 10 mg/kg CFTRact-J027 1 hour
before loperamide administration also was effective in
normalizing stool output and water content in loperamide-
treated mice, with no effect in control mice (Figure 4A).
The median effective dose for oral administration was
0.5 mg/kg, which was substantially lower than that for IP
administration (Figure 4B). In parallel studies, oral admin-
istration of the approved drugs lubiprostone or linaclotide
at 250- to 500-fold greater mg/kg doses than given to hu-
man beings for treatment of constipation were less effective
in normalizing stool output, producing 50% and 35%,
respectively, of the maximal CFTRact-J027 response
(Figure 4C).CFTRact-J027 Actions on Intestinal Transit,
Motility, and Fluid Transport
CFTRact-J027 action on intestinal transit and motility
was measured in vivo and in isolated intestinal strips.Whole-gut transit time, as measured by the appearance of a
marker in the stool after bolus oral gavage at the time of IP
loperamide and CFTRact-J027 administration, was normal-
ized by CFTRact-J027 (Figure 5A, left panel). CFTRact-J027
had no effect on whole-gut transit time in cystic ﬁbrosis
mice (right panel). In vitro measurements of intestinal
contraction showed no effect of CFTRact-J027 added alone
or in the presence of 10 mmol/L loperamide in isolated
mouse ileum and colon strips (Figure 5B). CFTRact-J027
thus may increase intestinal transit in vivo by stimulating
motility by secretion-induced stretch of the gut wall or
other indirect mechanisms, without direct effect on intes-
tinal smooth muscle. The lack of compound effect on
loperamide-induced suppression of intestinal contractions
shows that CFTRact-J027 does not work by antagonizing the
opioid effect.
To directly investigate the effects of CFTRact-J027 on
intestinal ﬂuid secretion and absorption, an in vivo closed-
intestinal loop model was used. CFTRact-J027 was injected
into closed midjejunal loops and ﬂuid accumulation was
measured at 90 minutes. CFTRact-J027 produced a 140%
increase in loop weight/length ratio, indicating ﬂuid
secretion into the intestinal lumen in wild-type mice
(Figure 5C, upper panel), but was without effect in cystic
Figure 4. Orally administered CFTRact-J027 normalizes stool output and water content in loperamide-treated mice. (A)
Study protocol (left) and stool output, pellet number, and water content as performed in Figure 3 (means ± SEM, 6 mice per
group). (B) Dose-response study of CFTRact-J027 administered orally in loperamide-treated mice (4–6 mice per group). (C)
Same study as shown in panel A, but with oral lubiprostone (Lub) (0.5 mg/kg) or linaclotide (Lin) (0.5 mg/kg) (5–6 mice per
group). One-way analysis of variance, *P < .05, **P < .01, ***P < .001. Veh, vehicle.
May 2016 CFTR Activator for Constipation 323ﬁbrosis mice (lower panel), supporting a CFTR-selective
mechanism of action. A closed-loop model also was used
to study CFTRact-J027 action on intestinal ﬂuid absorption.
Fluid without or with CFTRact-J027 was injected into closed
midjejunal loops of cystic ﬁbrosis mice (to avoid con-
founding ﬂuid secretion) and ﬂuid absorption was
measured at 30 minutes. CFTRact-J027 did not affect in-
testinal ﬂuid absorption (Figure 5D).CFTRact-J027 Pharmacology and Toxicity in Mice
The in vitro metabolic stability of CFTRact-J027 was
measured by incubation with mouse liver microsomes in the
presence of reduced nicotinamide adenine dinucleotide
phosphate. CFTRact-J027 was metabolized rapidly, with an
approximately 21-minute elimination half-life, with only 7%
of the original compound remaining at 60 minutes
(Figure 6A).
Pharmacokinetics was measured in mice after bolus
intraperitoneal or oral administration of 10 mg/kg CFTRact-
J027. After IP administration, the serum CFTRact-J027 con-
centration decreased with an elimination half-life ofapproximately 16 minutes, and was undetectable at 150
minutes (Figure 6B). After oral administration, the serum
CFTRact-J027 concentration reached 180 nmol/L at 30 mi-
nutes and was undetectable at other time points
(Figure 6B). Together, these results suggest rapid compound
metabolism by liver, resulting in minimal systemic exposure
of orally administered CFTRact-J027.
Preliminary toxicologic studies of CFTRact-J027 were
performed in cell cultures and mice. CFTRact-J027, at a
concentration of 25 mmol/L, which is near its solubility
limit, did not show cytotoxicity as measured by the Alamar
Blue assay (Figure 6C). In the 7-day–treated mice, CFTRact-
J027 did not affect the major serum chemistry and blood
parameters (Table 1), and it did not change body weight or
produce airway/lung ﬂuid accumulation (Figure 6D).
Finally, to determine whether chronically administered
CFTRact-J027 retained efﬁcacy, mice were treated orally for
7 days with 10 mg/kg CFTRact-J027 or vehicle, and loper-
amide was given 1 hour after the ﬁnal dose. Figure 6E
shows that chronically administered CFTRact-J027 remained
effective in normalizing stool output and water content after
loperamide.
Figure 5. CFTRact-J027 actions on intestinal ﬂuid secretion, absorption, and motility. (A) Whole-gut transit time in control
and loperamide-treated wild-type (left) and cystic ﬁbrosis (right) mice (means ± SEM, 3–5 mice per group). Where indicated,
loperamide (0.3 mg/kg) and CFTRact-J027 (10 mg/kg) were administered IP at 0 time (means ± SEM, 6 mice per group).
(B) Contraction of isolated intestinal strips. Ileum and colon strips (w2 cm) were suspended in Krebs–Henseleit buffer with 0.5
g and 0.2 g tension, respectively. Where indicated, CFTRact-J027, loperamide, and carbachol were added to the organ
chamber. (C) Intestinal ﬂuid secretion was measured in closed midjejunal loops in wild-type mice (upper panel). Loops
were injected with 100 mL vehicle or 100 mg CFTRact-J027. Loop weight/length was measured at 90 minutes (means ± SEM, 4
loops per group). Similar experiments were performed in cystic ﬁbrosis mice (lower panel, 4 loops per group). (D) Intestinal ﬂuid
absorption was measured in midjejunal loops in cystic ﬁbrosis mice. Loops were injected with 100 mL vehicle or 100
microgram CFTRact-J027. Loop weight/length was measured at 30 minutes. Summary of ﬂuid absorption (means ± SEM, 4
loops per group). One-way analysis of variance was used for panel A , Student’s t test was used for panel C and D. **P < .01,
***P < .001.
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We identiﬁed by high-throughput screening a nanomolar
afﬁnity, small-molecule CFTR activator, CFTRact-J027, and
showed its prosecretory action in mouse intestine and its
efﬁcacy in normalizing stool output in a loperamide-induced
mouse model of constipation. Constipation remains a sig-
niﬁcant clinical problem in outpatient and hospitalized
settings. Opioid-induced constipation is a common adverse
effect in patients after surgery, undergoing chemotherapy,
and with chronic pain.
CFTR-targeted activation adds to the various mecha-
nisms of action of anticonstipation therapeutics. It is notable
that pure CFTR activation is able to produce a robust
Cl- current and ﬂuid secretion response in the intestine,without causing global increase of cyclic nucleotide con-
centration, direct stimulation of intestinal contractility, or
alteration of intestinal ﬂuid absorption. Linaclotide, a pep-
tide agonist of the guanylate cyclase C receptor that in-
creases intestinal cell cGMP concentration, has the closest
mechanism of action to a pure CFTR activator. Linaclotide
inhibits activation of colonic sensory neurons and activates
motor neurons, which reduces pain and increases intestinal
smooth muscle contraction; in addition, an increase in cGMP
concentration in enterocytes may activate CFTR and have a
prosecretory action.4,5 The uroguanylin analog plecanatide
has a similar mechanism of action and preliminary data
showed comparable efﬁcacy with linaclotide for treatment
of chronic constipation.16 A second approved drug, the
Figure 6. CFTRact-J027 pharmacokinetics, tissue distribution, and toxicity. (A) In vitro metabolic stability of CFTRact-J027
assayed in mouse liver microsomes after incubation for speciﬁed times. (B) Standard plasma concentration curve for liquid
chromatography–mass spectrometry (left) and kinetics of CFTRact-J027 concentration in plasma determined by liquid chro-
matography–mass spectrometry after bolus IP or oral administration of 10 mg/kg CFTRact-J027 at zero time (right, means ±
SEM, 3 mice per group). (C) In vitro toxicity measured by Alamar Blue assay in FRT cells (means ± SEM; n ¼ 3 cultures). (D)
Body weight and lung wet/dry weight ratio in mice receiving 10 mg/kg CFTRact-J027 orally for 7 days (means ± SEM, 5 mice
per group). (E) Chronic administration protocol (left) and efﬁcacy of oral CFTRact-J027 after 7-day administration (means ±
SEM, 5 mice per group). Student t test, *P < .05, **P < .01, ***P < .001. conc, concentration; Lop, loperamide.
May 2016 CFTR Activator for Constipation 325prostaglandin E analog lubiprostone, is thought to activate a
putative enterocyte ClC-2 channel6 and it has been reported
that lubiprostone also activates CFTR via prostanoid-
receptor signaling.17 Compared with these drugs, a pure
CFTR activator has a single, well-validated mechanism of
action and does not produce a global cyclic nucleotide
response in multiple cell types. Of note, linaclotide and
lubiprostone showed limited efﬁcacy in clinical trials. In
terms of the primary efﬁcacy end point (weekly frequency
of 3 complete spontaneous bowel movements [CSBM] and
increase of 1 CSBM from baseline for at least 9 weeks of
the 12-week treatment period), linaclotide was effective in
approximately 20% of chronic constipation patients, of
whom approximately 5% also responded to placebo, and
linaclotide signiﬁcantly increased CSBM per week (w2.5)
compared with placebo (0.9).18 The overall response rate to
lubiprostone was approximately 13% in constipation-pre-
dominant irritable bowel syndrome patients, of whom
approximately 7% responded to placebo.19 Based on ourmouse data showing substantially greater efﬁcacy of
CFTRact-J027 compared with supramaximal doses of lina-
clotide or lubiprostone, we speculate that CFTR activators
may have greater efﬁcacy in clinical trials.
CFTRact-J027 is substantially more potent for activation
of wild-type CFTR than VX-770 (ivacaftor), the Food and
Drug Administration–approved drug for treatment of CF
caused by certain CFTR gating mutations. In FRT cells
expressing wild-type CFTR, short-circuit current measure-
ment showed nearly full activation of CFTR by CFTRact-J027
at 3 mmol/L whereas VX-770 maximally activated CFTR by
only 15% (data not shown). However, CFTRact-J027 was
substantially less potent than ivacaftor as a potentiator of
defective chloride channel gating of the most common CF-
causing mutation, DF508, which is not unexpected
because potentiator efﬁcacy in CF is mutation-speciﬁc. In
addition to its potential therapeutic utility for constipation,
a small-molecule activator of wild-type CFTR may be useful
for treatment of chronic obstructive pulmonary disease and
Table 1.Complete Blood Count and Serum Chemistries
of Mice Treated for 7 Days With 10 mg/kg
CFTRact-J027 or Vehicle Orally Once per Day
Vehicle CFTRact-J027 P value
Hemoglobin level, g/dL 13.3 ± 0.2 12.8 ± 0.3 >.05
Leukocyte level, 103/mL 1.9 ± 0.3 1.9 ± 0.5 >.05
Thrombocyte level, 103/mL 790 ± 109 900 ± 48 >.05
Total protein level, g/dL 4.7 ± 0.2 5.2 ± 0.1 >.05
Albumin level, g/dL 2.6 ± 0.1 2.9 ± 0.03 >.05
Globulin level, g/dL 2.1 ± 0.1 2.2 ± 0.1 >.05
ALT level, U/L 52 ± 16 44 ± 6 >.05
AST level, U/L 131 ± 17 105 ± 11 >.05
ALP level, U/L 47 ± 8.5 53 ± 2.5 >.05
Total bilirubin level, mg/dL 0.1 ± 0 0.1 ± 0 >.05
Glucose level, mg/dL 156 ± 22 164 ± 6 >.05
Cholesterol level, mg/dL 121 ± 14 121 ± 6 >.05
CK level, U/L 344 ± 85 312 ± 62 >.05
Sodium level, mmol/L 149 ± 2.3 151 ± 0.7 >.05
Potassium level, mmol/L 5.0 ± 0.1 4.4 ± 0.1 >.05
Chloride level, mmol/L 113 ± 1 115 ± 1 >.05
Calcium level, mg/dL 8.5 ± 0.2 8.5 ± 0.04 >.05
Phosphorus level, mg/dL 6.6 ± 0.9 6.8 ± 0.3 >.05
BUN level, mg/dL 15.3 ± 3 18.4 ± 1.2 >.05
Creatinine level, mg/dL 0.2 ± 0 0.2 ± 0 >.05
Bicarbonate level, mmol/L 15.3 ± 1.6 16 ± 1.7 >.05
NOTE. Mean ± SEM are shown, 5 mice per group. Student’s t
test was used.
ALP, alkaline phosphatase; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; BUN, blood urea nitrogen;
CK, creatinine kinase.
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tion, dry eye, and cholestatic liver disease.20–22
There have been several prior reports on the biological
properties of the core quinoxalinone scaffold found in
CFTRact-J027. Substituted quinoxalinones were reported as
selective antagonists of the membrane efﬂux transporter
multiple-drug-resistance protein 1.23 Quinoxalinones also
have been reported to show antidiabetic activity by stimu-
lating insulin secretion in pancreatic INS-1 cells,24 and
inhibitory activity against serine proteases for potential
therapy of thrombotic disorders.25 Recently, quinoxalinones
have been reported to inhibit aldose reductase.26 These re-
ports suggest that the quinoxalinone scaffold has drug-like
properties. Synthetically, quinoxalinone can be prepared in
1–4 steps from commercially available starting materials,27
which allows facile synthesis of targeted analogs.
In addition to compound-speciﬁc, off-target actions, the
potential side-effect proﬁle of a CFTR activator could include
prosecretory activity in the airway/lungs and various glan-
dular and other epithelia. Off-target effects for constipation
therapy could be limited by oral administration of a CFTR
activator with limited intestinal absorption and/or rapid
systemic clearance to minimize systemic exposure. CFTRact-
J027, when administered orally at a high dose (10 mg/kg),showed very low bioavailability with blood levels well below
the EC50 for CFTR activation, which may be owing to ﬁrst-
pass effect as evidenced by its rapid in vitro metabolism in
liver microsomes. CFTRact-J027 did not show signiﬁcant
in vitro cytotoxicity at a concentration of 25 mmol/L, more
than 100-fold greater than its EC50 for CFTR activation, or
in vivo toxicity in mice in a 7-day study at a maximal efﬁ-
cacious dose. The potentially most signiﬁcant off-target
action, stimulation of lung/airway ﬂuid secretion, was not
seen as evidenced by normal lung water content in the 7-
day–treated mice. These limited toxicity studies offer proof
of concept for application of a CFTR activator in con-
stipation, but will require a more extensive data set for
further preclinical development.
In summary, our data provide evidence for the prose-
cretory action of a CFTR activator in mouse intestine and
proof of concept for its use in the treatment of various types
of constipation, which could include opioid-induced con-
stipation, chronic idiopathic constipation, and irritable
bowel syndrome with constipation predominance.References
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